ArticleBMJ paediatrics open2026
Side effects of medical therapy for non-neurogenic lower urinary tract symptoms in children: a UK-based single centre retrospective case-note review.
Article in BMJ paediatrics open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe aimed to study time to, and reason for, discontinuation of medication to manage daytime lower urinary tract symptoms (LUTS) in children, the impact of side effects (SE) on tolerance and the time-burden of failed treatment.
designUK-based single centre retrospective case-note review.
settingTertiary level nurse-led urology clinic. PATIENTS: 200 children prescribed anti-cholinergics and/or mirabegron to manage daytime LUTS due to overactive bladder between 2016 and 2021.
main outcome measuresAge and sex, medications prescribed, time to and reason for discontinuation of medications and SE reported.
results200 children (71% female), median age 11 (IQR 9-13) years prescribed 371 medications were included. 106 were prescribed a second medication, 50 a third, 17 a fourth medication (2 dual-therapy regimens). 147 received oxybutynin, 94 (64%) discontinued it for reasons other than treatment success after 337 (94-456) days, 47 (32%) due to SE, a significant number due to mood changes (15, 32%, p<0.05). For oxybutynin, increased age and presence of SE resulted in shorter time to discontinuation (p=0.047). 100 received tolterodine, 63 (63%) discontinued it after 312 (147-553) days, 25 (25%) due to SE, 11 (44%) for mood changes. Children prescribed solifenacin (86) and mirabegron (38) had significantly fewer SE compared with oxybutynin (solifenacin p=0.020, mirabegron p=0.025).
conclusionsThis study shows that oxybutynin and tolterodine were frequently discontinued due to SE, many of which are classified as 'psychiatric' or 'nervous system' disorders. Solifenacin and mirabegron were better tolerated: future research should investigate optimal medical therapy for LUTS in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.